Pharma major Lupin today announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit 3) facility. The inspection at the site was conducted between June 12, 2017 and June 16, 2017.

This was a Pre-approval inspection for Albuterol Sulfate Inhalation product. Lupin’s Pithampur (Unit 3) facility manufactures Dermatological Products, Dry Product Inhalers and Metered Dose Inhalers.

Nilesh Gupta, Managing Director, Lupin said, ''The receipt of the EIR for our Pithampur Unit 3 is an encouraging development. This is a validation of our commitment to maintain the highest standards in quality and compliance across our facilities.''

Shares of the company declined Rs 24.85, or 2.96%, to settle at Rs 815.05. The total volume of shares traded was 227,303 at the BSE (Monday).